Transaction Overview
交易概览

• KiOmed Pharma licensed out the development and commercialization rights for its KiOmedine^vsOne, to Hansoh Pharma for China’s mainland, Macau and Taiwan.
  比利时Kiomed Pharma SA将其研发的骨关节炎产品在大中华区的独家开发、生产及商业化权利授权给翰森制药。
• KiOmed Pharma is eligible to receive upfront fee and milestone payments of up to €66 million plus double-digit royalties on future product sales.
  Kiomed Pharma将会收到首付款，注册和销售里程碑付款，以及一定比例的销售提成。
• KiOmedine^vsOne is a non-animal sourced chitosan injection that has been launched in Europe for the treatment of knee osteoarthritis.
  KiOmedine^vsOne是基于全球首款独家非动物KiOmedine® CM－壳聚糖的新一代用于治疗膝关节骨关节炎的单次注射剂。
• YAFO Capital (Shanghai) acted as advisor on this transaction for KiOmed. 
  雅法资本担任本次交易的顾问。

(26 September, 2022, Shanghai, China ) HERSTAL, Belgium & SHANGHAI--KiOmed Pharma, a Belgian biotechnology company with a focus on the development, manufacture and distribution of safe and effective medical devices based on a medical-grade highly pure natural chitosan-derivative, and Hansoh Pharmaceutical Group Company Limited (SEHK: 3692), a leading biopharmaceutical company in Asia, today announced a license agreement for the development and commercialization of KiOmedine^vsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee osteoarthritis, in China’s mainland, Macau and Taiwan (the territory). YAFO Capital (Shanghai) acted as advisor on this transaction for KiOmed Pharma.
9月26日，翰森制药获得KiOmed Pharma SA（「KiOmed」）的独家许可，在中国大陆、澳门及台湾开发及商业化KiOmedine^vsOne用于骨关节炎的治疗。 雅法资本担任本次交易的顾问。

Under the terms of the agreement, KiOmed will receive an upfront payment and will be eligible to receive development, regulatory and commercial milestones of up to € 66 million, as well as tiered royalties on future product sales. Hansoh will receive exclusive rights to develop and commercialize KiOmedine^vsOne and its future extensions in the territory. KiOmed retains the right to develop and commercialize KiOmedine^vsOne in all other global markets.
Osteoarthritis is a progressive and disabling disease affecting about 250 million people worldwide. According to a recent epidemiology report, the prevalence of knee osteoarthritis in China is 8.1%. As the population in China is aging rapidly, disease burden caused by knee osteoarthritis continues to rise while safe and effective treatment options are still lacking. 
“We are very excited to partner with Hansoh Pharma, one of the largest biopharmaceutical entities in Greater China. We believe that with Hansoh’s impactful presence in China, their support will be essential to bring this long-acting treatment to the large population of patients suffering from osteoarthritis in China,” said Mr. François Blondel, Founder and Executive Chairman of the Board of KiOmed Pharma. “We launched KiOmedine^vsOne last year in several regions of Europe, and the feedback we continue to receive from osteoarthritis patients and physicians is great. With just one single injection to the knee, it can provide symptoms relief including pain, stiffness, and function improvement for more than 6-month. It is the world-first next generation non-animal sourced chitosan injection with a potential safety advantage over animal-sourced chitosan,” added Dr. Houtaï Choumane, CEO and Managing Director of KiOmed.
“KiOmed is a leader and an expert in developing natural chitosan products to fulfill unmet medical needs in different spaces. Osteoarthritis negatively impacts an individual’s quality of life and creates a large burden for the patients and their families. We are very glad to see KiOmed’s product (KiOmedine^vsOne) will help to solve this problem,” said Eliza Sun, Executive Director of the Board of Hansoh Pharma. “We are also very excited to partner with them and bring this unique product to much needed patients in China.”
根据许可协议，被许可人将负责KiOmedinevsOne及其未来骨关节炎拓展适应症于授权区域的开发、注册审批及 商业化，并将支付预付款和开发、注册及基于销售的商业化里程碑潜在付款合计不超过6600万欧元，以及基于产品未来净销售额的两位数分级特许权使用费。

About KiOmedinevsOne
关于交易资产

KiOmedine^vsOne is a new generation single injection for the treatment of knee osteoarthritis based on world-first exclusive animal free KiOmedine® CM-Chitosan. KiOmedine® CM-Chitosan is a highly purified polysaccharide derived from Agaricus Bisporus (button mushroom) and a patented technology made in Belgium, resulting from years of research and innovation. Different from hyaluronic acid, KiOmedine^vsOne has dual mechanism of action to tackle osteoarthritis discomfort and other symptoms by reducing oxidative stress and enhancing joint lubrication. Clinical studies have shown that after a single injection of KiOmedine^vsOne, significant pain reduction was observed within 2 weeks and the WOMAC pain score was reduced by 66%, with a long-lasting osteoarthritis symptom reduction for at least 6 months. KiOmedine^vsOne is a regulated health product which bears the CE mark under this regulation. It has been launched in Europe in 2021.
KiOmedine^vsOne是基于全球首款独家非动物KiOmedine® CM－壳聚糖的新一代用于治疗膝关节骨关节炎的单次注射剂。临床研究表明，单次注射KiOmedinevsOne后，2周内疼痛明显减轻，骨关节炎指数(WOMAC)疼痛评分降低了66%，骨关节炎症状的减轻至少可持续6个月。 KiOmedine^vsOne已获得CE认证，并已于2021年在欧洲上市。

About KiOmed Pharma
关于KiOmed

Based in Belgium, KiOmed Pharma has a history of innovation and expertise in exclusive natural chitosan chemistry. The company develops a unique pipeline of medical devices that address unmet medical needs in high impact pathologies and major social burdens such as osteoarthritis, skin aging and ophthalmology. KiOmed Pharma's innovative pipeline is based on a solid building block exclusive technology: KiOmedine®, a medical-grade highly pure natural chitosan-derivative. 
For more information, please visit https://www.kiomedpharma.com/.
KiOmed总部位于比利时，在独家天然壳聚糖化学方面有着相当的创新和专业历史 积累。KiOmed开发了独特的医疗设备管线专注解决疾病影响重大、社会负担严重的临床未竟医疗需求，如骨关节炎、皮肤老化和眼科等领域。
更多信息请访问https://www.kiomedpharma.com/

About Hansoh Pharma
关于翰森制药

Hansoh Pharma (3692.HK), one of the largest biopharmaceutical companies in China, is committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders.
Founded in 1995, Hansoh has fully integrated research and development, manufacturing, and commercial capabilities, supporting leading positions in oncology, central nervous system (CNS) disorders, infectious diseases, gastrointestinal disorders, diabetes, autoimmune diseases, and other main therapeutic areas in China. With the support of over 1,400 highly skilled R&D professionals, Hansoh has successfully developed multiple internally discovered drug candidates into NMPA-approved innovative medicines. For more information, please visit www.hspharm.com.
翰森制药（HK.03692）的主要经营主体豪森药业成立于1995年，是中国领先的创新驱动型制药公司，重点关注抗肿瘤、中枢神经系统、抗感染和糖尿病等重大疾病治疗领域。公司连续多年位居中国医药工业百强榜前30强、中国医药研发产品线最佳工业企业前3强，是国家重点高新技术企业、国家技术创新示范企业。经过20多年的持续研发投入，截至目前，公司已上市5个1类创新药，在研药物百余个，20多个创新药进入临床阶段，形成了丰富的管线。公司的生产质量体系已获得美国FDA、欧盟EMA、日本PMDA的官方认证，制剂成品及原料药获准销往欧美日等国家和地区。

About YAFO Capital
关于雅法资本

Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. During the past 9 years, YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has an experienced global transaction and industry team to support our client’s transactions. YAFO ranked as the No. 1 advisor for China cross border licensing transactions in 2021.  For more information, please visit www.yafocapital.com
雅法资本成立于2013年，作为新型投资和金融服务机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法全球医疗专注于医药跨境交易，基于雅法在全球广泛的人脉与资源网络，在9年内成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。2021年雅法中国跨境授权及并购交易数量排名第一。
更多信息请访问 www.yafocapital.com

Contact
联系我们

Wendi Xiang 相文迪
Vice President
wxiang@yafocapital.com

参考：https://www.businesswire.com/news/home/20220926005128/en/KiOmed-Pharma-and-Hansoh-Pharma-Announce-License-Agreement-for-KiOmedinevsOne-in-China%E2%80%99s-Mainland-Macau-and-Taiwan